Biopharmaceutical New Technologies (BioNTech) is a global biotechnology company aspiring to translate science into survival by developing new immunotherapies utilizing the full potential of the immune system to fight cancer and infectious diseases. BioNTech is headquartered in Mainz, Germany, and operates globally with almost 7.000 pioneers. Our work is powered by one mission: Improving the health of people worldwide. We believe that scientific rigor and passion are the driving forces that are essential for innovative progress. BioNTech was founded in 2008 by scientists and physicians to translate science into survival by combining fundamental research and operational excellence. At BioNTech, we have been conducting fundamental research of mRNA technologies in the field of individualized cancer medicine for more than a decade. Some of our colleagues, including our co-founders, have been researching and developing mRNA-based vaccines for more than 25 years. Ready to join us on this journey? Explore the opportunities and become part of a team that aspires to turn bold ideas into real-world solutions: https://www.biontech.com/int/en/home/careers.html 🔗 Privacy Statement: https://www.biontech.com/int/en/home/data-privacy-statement.html 🔗 Imprint: https://www.biontech.com/int/en/home/imprint.html
我们正在追踪 BioNTech SE 的市场扩张
新增 合作伙伴 活动 — 刚出现 2 个新信号。
BioNTech SE 的国际扩张与竞争对手的对比情况
BioNTech SE你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 BioNTech SE你 | 0 | 0 | — | 0 | 0 |
Director Safety Physician
查看职位Mainz, Rhineland-Palatinate, Germany · 3天前
Associate Technician Facility Management (m/w/d)
查看职位Frankfurt Rhine-Main Metropolitan Area · 4天前
Director, Regional Logistics Operations US
查看职位Gaithersburg, MD · 2周前
没有进行中的营销活动
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
BioNTech的实验性乳腺癌药物在中国试验中表现优于罗氏的Kadcyla，显示出超越Covid疫苗的未来增长潜力。
辉瑞-BioNTech 2025-2026年mRNA新冠疫苗在老年人和高风险群体中显示出强烈免疫反应，对LP.8.1变种的中和抗体增加4倍。
BioNTech报告COVID疫苗和癌症药物BNT327的临床突破，有望提升销售并加速肿瘤学发展。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 BioNTech SE 的业务、市场和增长信号的快速解答。
